Traws Pharma Inc (TRAW) Stock Price, Quote & News - Mboum

Company Profile

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 759 3680

Fax: 267 759 3681

Website: www.trawspharma.com

Address:

12 Penns Trail, Newtown, United States

Twitties00 Jul. 28 at 7:26 PM

$TRAW AND then there are all these guys that hopped in at an average of $8.80. Best of the Best.

0 · Reply

Twitties00 Jul. 28 at 7:25 PM

$TRAW CEO was in charge of M & A and all licensing deals for Merck. He’s a partner in Orbimed which is recognized as one of the top Biotech investment funds on the 🌎. He sold Reviral for 500 mil and they didn’t have anything near what Traws may with these two antivirals.

0 · Reply

Twitties00 Jul. 28 at 7:22 PM

$TRAW not only is TRAW’s Chief Medical Officer the Former CDC Director for Trump, he also founded the Human Institute of Virology at University of Maryland. He’s a fellow at the Heritage Foundation and just helped the Director of the CIA write the article that was just published on Covid’s origins.

0 · Reply

Twitties00 Jul. 28 at 7:09 PM

$TRAW if the two antivirals are best in class or even close, OR if even one is then the annual market is in the BILLIONS. These results are epic. So are the seasonal flu results. Toss in some Bird Flu and the possibility of stockpiling and…🚀

0 · Reply

janon10 Jul. 26 at 11:42 PM

$TRAW RSI 14 at 24,22 on a high low. Expecting some news either next week or 4 Aug. GL to all, lets bank.

0 · Reply

janon10 Jul. 25 at 8:02 PM

$TRAW hope you added on this high low

0 · Reply

Schube1255 Jul. 25 at 8:00 PM

$TRAW wen down payment on my Ferrari?

1 · Reply

Jbjb90 Jul. 25 at 5:22 PM

$LXRX $TRAW added to both with them both being down today

0 · Reply

_ICEMAN Jul. 24 at 11:49 PM

$TRAW next up

0 · Reply

Twitties00 Jul. 24 at 9:46 PM

$TRAW Traws is going head to head with Xofluza for seasonal influenza and going up against Bird Flu in Southeast Asia. The market for flu antivirals without a pandemic is BILLIONS. The potential for stockpiling is BILLIONS. The potential in a pandemic is many BILLIONS. That’s not to mention the Covid/Ling Covid antiviral which has a potential market of BILLIONS. CMO is former CDC Director in with Trump and CEO was in charge of M&A for Merck. CEO also venture partner in Orbimed with strong history of selling his companies. Thank you for your attention to this matter. 🇺🇸🐓🦠💸⏳💎

0 · Reply

Latest News on TRAW

Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions

Jun 30, 2025, 6:30 AM EDT - 4 weeks ago

Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions

Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib

Jun 3, 2025, 7:00 AM EDT - 7 weeks ago

Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib

Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness

May 27, 2025, 8:00 AM EDT - 2 months ago

Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness

Traws Pharma Reports First Quarter 2025 Results and Business Highlights

May 15, 2025, 7:00 AM EDT - 2 months ago

Traws Pharma Reports First Quarter 2025 Results and Business Highlights

Traws Pharma, Inc. (TRAW) Virtual Investor Event Transcript

Apr 1, 2025, 8:50 PM EDT - 4 months ago

Traws Pharma, Inc. (TRAW) Virtual Investor Event Transcript

Traws Pharma Announces Management Updates

Mar 28, 2025, 4:30 PM EDT - 4 months ago

Traws Pharma Announces Management Updates

Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET

Mar 26, 2025, 7:30 AM EDT - 4 months ago

Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET

Traws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICAR

Mar 25, 2025, 7:30 AM EDT - 4 months ago

Traws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICAR

Traws Pharma's Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR

Mar 21, 2025, 7:00 AM EDT - 4 months ago

Traws Pharma's Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR

Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil

Mar 3, 2025, 7:00 AM EST - 5 months ago

Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil

Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule

Feb 28, 2025, 7:00 AM EST - 5 months ago

Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule

Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu

Jan 23, 2025, 7:00 AM EST - 6 months ago

Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu

Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program

Jan 10, 2025, 5:55 PM EST - 7 months ago

Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program

Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval

Dec 30, 2024, 8:00 AM EST - 7 months ago

Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval

Traws Pharma stock soars 200% on encouraging bird flu drug data

Dec 23, 2024, 12:00 PM EST - 7 months ago

Traws Pharma stock soars 200% on encouraging bird flu drug data

Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu

Dec 23, 2024, 7:00 AM EST - 7 months ago

Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu

Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results

Nov 14, 2024, 4:30 PM EST - 9 months ago

Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results

Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil

Oct 8, 2024, 7:30 AM EDT - 10 months ago

Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil

Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor

Sep 30, 2024, 7:30 AM EDT - 10 months ago

Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor

Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors

Sep 20, 2024, 7:30 AM EDT - 11 months ago

Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors

Traws Pharma, Inc. Announces Special Shareholders Meeting Results

Sep 17, 2024, 4:05 PM EDT - 11 months ago

Traws Pharma, Inc. Announces Special Shareholders Meeting Results

Traws Pharma, Inc. (TRAW) Corporate Update Call Transcript

Aug 20, 2024, 9:02 AM EDT - 1 year ago

Traws Pharma, Inc. (TRAW) Corporate Update Call Transcript

Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights

Aug 15, 2024, 7:00 AM EDT - 1 year ago

Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights

Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET

Aug 14, 2024, 4:30 PM EDT - 1 year ago

Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET

Traws Pharma Announces New Employee Inducement Grants

Apr 2, 2024, 7:15 AM EDT - 1 year ago

Traws Pharma Announces New Employee Inducement Grants

Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024

Mar 8, 2024, 8:00 AM EST - 1 year ago

Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024

Onconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's

Dec 8, 2023, 4:05 PM EST - 1 year ago

Onconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's

Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference

Nov 28, 2023, 8:00 AM EST - 1 year ago

Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference

Onconova Therapeutics, Inc. (ONTX) Q3 2023 Earnings Call Transcript

Nov 14, 2023, 8:18 PM EST - 1 year ago

Onconova Therapeutics, Inc. (ONTX) Q3 2023 Earnings Call Transcript

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

Nov 14, 2023, 4:05 PM EST - 1 year ago

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

Nov 7, 2023, 4:05 PM EST - 1 year ago

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL

Nov 2, 2023, 10:37 AM EDT - 1 year ago

Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL

Onconova Expands Leadership Team with Two Key Appointments

Oct 24, 2023, 8:00 AM EDT - 1 year ago

Onconova Expands Leadership Team with Two Key Appointments

Promising Preclinical Narazaciclib Data Presented at MCL Meeting

Oct 19, 2023, 8:00 AM EDT - 1 year ago

Promising Preclinical Narazaciclib Data Presented at MCL Meeting

Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress

Sep 28, 2023, 8:00 AM EDT - 1 year ago

Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress

Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

Onconova Therapeutics, Inc. (ONTX) Q2 2023 Earnings Call Transcript

Aug 10, 2023, 9:08 PM EDT - 2 years ago

Onconova Therapeutics, Inc. (ONTX) Q2 2023 Earnings Call Transcript

Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma

Jun 14, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma

Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting

Jun 5, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting

Onconova Therapeutics, Inc. (ONTX) Q1 2023 Earnings Call Transcript

May 15, 2023, 9:11 PM EDT - 2 years ago

Onconova Therapeutics, Inc. (ONTX) Q1 2023 Earnings Call Transcript

Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 15, 2023, 4:18 PM EDT - 2 years ago

Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial Cancer

May 12, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial Cancer

Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2023 Financial Results on May 15, 2023

May 4, 2023, 4:05 PM EDT - 2 years ago

Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2023 Financial Results on May 15, 2023

Onconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark Gelder

Apr 6, 2023, 4:05 PM EDT - 2 years ago

Onconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark Gelder

Onconova Therapeutics and Pangea Biomed Enter into Research Collaboration to Identify Biomarkers of Response to Rigosertib

Mar 23, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics and Pangea Biomed Enter into Research Collaboration to Identify Biomarkers of Response to Rigosertib

Onconova Therapeutics, Inc. (ONTX) Q4 2022 Earnings Call Transcript

Mar 16, 2023, 9:56 PM EDT - 2 years ago

Onconova Therapeutics, Inc. (ONTX) Q4 2022 Earnings Call Transcript

Onconova Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update

Mar 16, 2023, 4:04 PM EDT - 2 years ago

Onconova Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update

Onconova Therapeutics Announces Upcoming Poster Presentations at the AACR Annual Meeting

Mar 15, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics Announces Upcoming Poster Presentations at the AACR Annual Meeting

Onconova Therapeutics to Provide Corporate Update and Announce Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023

Mar 9, 2023, 4:05 PM EST - 2 years ago

Onconova Therapeutics to Provide Corporate Update and Announce Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023

Onconova Therapeutics Presents Preclinical Data Characterizing Rigosertib's Mechanisms of Action at the AACR Targeting RAS Conference

Mar 7, 2023, 8:00 AM EST - 2 years ago

Onconova Therapeutics Presents Preclinical Data Characterizing Rigosertib's Mechanisms of Action at the AACR Targeting RAS Conference

Twitties00 Jul. 28 at 7:26 PM

$TRAW AND then there are all these guys that hopped in at an average of $8.80. Best of the Best.

0 · Reply

Twitties00 Jul. 28 at 7:25 PM

$TRAW CEO was in charge of M & A and all licensing deals for Merck. He’s a partner in Orbimed which is recognized as one of the top Biotech investment funds on the 🌎. He sold Reviral for 500 mil and they didn’t have anything near what Traws may with these two antivirals.

0 · Reply

Twitties00 Jul. 28 at 7:22 PM

$TRAW not only is TRAW’s Chief Medical Officer the Former CDC Director for Trump, he also founded the Human Institute of Virology at University of Maryland. He’s a fellow at the Heritage Foundation and just helped the Director of the CIA write the article that was just published on Covid’s origins.

0 · Reply

Twitties00 Jul. 28 at 7:09 PM

$TRAW if the two antivirals are best in class or even close, OR if even one is then the annual market is in the BILLIONS. These results are epic. So are the seasonal flu results. Toss in some Bird Flu and the possibility of stockpiling and…🚀

0 · Reply

janon10 Jul. 26 at 11:42 PM

$TRAW RSI 14 at 24,22 on a high low. Expecting some news either next week or 4 Aug. GL to all, lets bank.

0 · Reply

janon10 Jul. 25 at 8:02 PM

$TRAW hope you added on this high low

0 · Reply

Schube1255 Jul. 25 at 8:00 PM

$TRAW wen down payment on my Ferrari?

1 · Reply

Jbjb90 Jul. 25 at 5:22 PM

$LXRX $TRAW added to both with them both being down today

0 · Reply

_ICEMAN Jul. 24 at 11:49 PM

$TRAW next up

0 · Reply

Twitties00 Jul. 24 at 9:46 PM

$TRAW Traws is going head to head with Xofluza for seasonal influenza and going up against Bird Flu in Southeast Asia. The market for flu antivirals without a pandemic is BILLIONS. The potential for stockpiling is BILLIONS. The potential in a pandemic is many BILLIONS. That’s not to mention the Covid/Ling Covid antiviral which has a potential market of BILLIONS. CMO is former CDC Director in with Trump and CEO was in charge of M&A for Merck. CEO also venture partner in Orbimed with strong history of selling his companies. Thank you for your attention to this matter. 🇺🇸🐓🦠💸⏳💎

0 · Reply

JohnSmith1212 Jul. 24 at 11:07 AM

0 · Reply

janon10 Jul. 24 at 10:19 AM

$TRAW so this go instant from 1,86 PM to 1,58. Got sense, ty for chipi shares.

0 · Reply

_ICEMAN Jul. 23 at 11:33 PM

$TRAW Next in line for a run

0 · Reply

janon10 Jul. 23 at 9:30 PM

$TRAW healthcare rotation coming. All profits from TDTH to $TRAW .

0 · Reply

50shadesoftrades Jul. 23 at 8:42 PM

$TRAW some of my fav charts. will post a few more $REE $TOVX

0 · Reply

ChartChartist Jul. 23 at 4:54 PM

$TRAW wants it slow and sure

0 · Reply

50shadesoftrades Jul. 23 at 4:00 PM

$TRAW nice chart getting vol

0 · Reply

janon10 Jul. 22 at 11:24 PM

$TRAW Mood

0 · Reply

Privatebryan Jul. 22 at 5:55 PM

$TRAW love it no-one is selling any shares just waiting for the rocket to launch!!!!

0 · Reply

Schube1255 Jul. 22 at 1:39 AM

$TRAW $RXRX $LAES

0 · Reply

Trade_Weaver Jul. 21 at 8:01 PM

$TRAW great day!

0 · Reply

50shadesoftrades Jul. 21 at 5:48 PM

$TRAW added for swing, Daily is crossing MAs and setting up for reversal

1 · Reply